Cytokinetics (CYTK) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $79.17 +0.50%
Revenue Growth %: -75.4%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -75.4%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $11.24 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Ennis (EBF) Reports In-Line Q1 EPS
- MP Materials seen largely insulated after China export-control move
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
